Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026

Pre-randomization Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) set-up data from the MODERATO II randomized, prospective, ...

Texas Biomed establishes new Tuberculosis Innovation and Technology Fund to improve research and treatments for world's deadliest infectious disease

Texas Biomedical Research Institute has established a new $2 million Tuberculosis Innovation and Technology Fund supported by philanthropic investment to accelerate future TB discoveries, therapies ...

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company developing nature-derived psychedelic therapeutics, today announced that the first ...

Texas Biomed advancing new approach methodologies (NAMs)

SAN ANTONIO, April 20, 2026 /PRNewswire/ -- Texas Biomedical Research Institute is advancing new tools -- known as new approach methodologies (NAMs) -- that can accelerate discoveries and drug ...
Morningstar

Orchestra BioMed Holdings Inc OBIO

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine

Company highlights global leadership in GMP ibogaine manufacturing and commitment to ethically sourced supplyNEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ...
Nasdaq

Orchestra BioMed Receives FDA Breakthrough Device Designation for Atrioventricular Interval Modulation Therapy to Address Uncontrolled Hypertension

Orchestra BioMed has announced that the FDA has granted Breakthrough Device Designation for its atrioventricular interval modulation (AVIM) therapy, aimed at treating over 7.7 million U.S. patients ...